Direct-acting Antiviral Drug Market Research Report by Type, Indication, Route, Distribution Channel, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030- Product Image

Sale

Direct-acting Antiviral Drug Market Research Report by Type, Indication, Route, Distribution Channel, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

Report
133 Pages
January 2023
Region: United States
360iResearch™
ID: 5336795

UP TO €855EUR$895USD£754GBP OFF until Mar 31^st 2023

The United States Direct-acting Antiviral Drug Market size was estimated at USD 2,013.27 million in 2022, USD 2,348.63 million in 2023 and is projected to grow at a CAGR of 14.09% to reach USD 5,781.36 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Direct-acting Antiviral Drug Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Direct-acting Antiviral Drug Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Direct-acting Antiviral Drug Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Direct-acting Antiviral Drug Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Direct-acting Antiviral Drug Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market is studied across NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA polymerase.
Based on Indication, the market is studied across Hepatitis C Virus, HIV Infection/ AIDS, Influenza, and Prophylaxis.
Based on Route, the market is studied across Intravenous, Oral, Subcutaneous, and Topical.
Based on Distribution Channel, the market is studied across Hospital Pharmacy, Online Drug Store, and Retail Pharmacy.
Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Direct-acting Antiviral Drug Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Direct-acting Antiviral Drug Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Direct-acting Antiviral Drug Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Direct-acting Antiviral Drug Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Direct-acting Antiviral Drug Market, including Boehringer Ingelheim International GmbH., Bristol-Myers Squibb Company, Cipla Limited, EVERSANA, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Direct-acting Antiviral Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Direct-acting Antiviral Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Direct-acting Antiviral Drug Market?
4. What is the competitive strategic window for opportunities in the United States Direct-acting Antiviral Drug Market?
5. What are the technology trends and regulatory frameworks in the United States Direct-acting Antiviral Drug Market?
6. What is the market share of the leading vendors in the United States Direct-acting Antiviral Drug Market?
7. What modes and strategic moves are considered suitable for entering the United States Direct-acting Antiviral Drug Market?

Frequently Asked Questions about the U.S. Direct-acting Antiviral Drug Market

What is the estimated value of the U.S. Direct-acting Antiviral Drug Market?

The U.S. Direct-acting Antiviral Drug Market was estimated to be valued at $2013.27 Million in 2022.

What is the growth rate of the U.S. Direct-acting Antiviral Drug Market?

The growth rate of the U.S. Direct-acting Antiviral Drug Market is 14.0%, with an estimated value of $5781.36 Million by 2030.

What is the forecasted size of the U.S. Direct-acting Antiviral Drug Market?

The U.S. Direct-acting Antiviral Drug Market is estimated to be worth $5781.36 Million by 2030.

Who are the key companies in the U.S. Direct-acting Antiviral Drug Market?

Key companies in the U.S. Direct-acting Antiviral Drug Market include Boehringer Ingelheim International GmbH., Bristol, Myers Squibb Company, Cipla Limited, EVERSANA, F. Hoffmann, La Roche Ltd., Merck & Co., Inc. and Pfizer Inc..

Report Attribute	Details
No. of Pages	133
Published	January 2023
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 2013.27 Million
Forecasted Market Value ( USD ) by 2030	$ 5781.36 Million
Compound Annual Growth Rate	14.0%
Regions Covered	United States
No. of Companies Mentioned	10

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing use for treatment of hepatitis C virus and liver cirrhosis
5.1.1.2. Rising product development and launch of new direct-acting antiviral medicines
5.1.2. Restraints
5.1.2.1. Difficulties in obtaining insurance approval for new HCV treatment regimens
5.1.3. Opportunities
5.1.3.1. Introduction of new direct-acting antiviral drugs
5.1.4. Challenges
5.1.4.1. unmeasured side effects associated with the Direct-Acting Antiviral drugs
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Direct-acting Antiviral Drug Market, by Type
6.1. Introduction
6.2. NS3/4A Protease
6.3. NS5A Protein
6.4. NS5B RNA-Dependent RNA polymerase

7. Direct-acting Antiviral Drug Market, by Indication
7.1. Introduction
7.2. Hepatitis C Virus
7.3. HIV Infection/ AIDS
7.4. Influenza
7.5. Prophylaxis

8. Direct-acting Antiviral Drug Market, by Route
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous
8.5. Topical

9. Direct-acting Antiviral Drug Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Drug Store
9.4. Retail Pharmacy

10. California Direct-acting Antiviral Drug Market
10.1. Introduction

11. Florida Direct-acting Antiviral Drug Market
11.1. Introduction

12. Illinois Direct-acting Antiviral Drug Market
12.1. Introduction

13. New York Direct-acting Antiviral Drug Market
13.1. Introduction

14. Ohio Direct-acting Antiviral Drug Market
14.1. Introduction

15. Pennsylvania Direct-acting Antiviral Drug Market
15.1. Introduction

16. Texas Direct-acting Antiviral Drug Market
16.1. Introduction

17. Competitive Landscape
17.1. FPNV Positioning Matrix
17.1.1. Quadrants
17.1.2. Business Strategy
17.1.3. Product Satisfaction
17.2. Market Ranking Analysis, By Key Player
17.3. Market Share Analysis, By Key Player
17.4. Product Portfolio Analysis, By Key Player
17.5. Competitive Scenario
17.5.1. Merger & Acquisition
17.5.2. Agreement, Collaboration, & Partnership
17.5.3. New Product Launch & Enhancement
17.5.4. Investment & Funding
17.5.5. Award, Recognition, & Expansion

18. Company Usability Profiles
18.1. Boehringer Ingelheim International GmbH.
18.2. Bristol-Myers Squibb Company
18.3. Cipla Limited
18.4. EVERSANA
18.5. F. Hoffmann-La Roche Ltd.
18.6. Merck & Co., Inc.
18.7. Novartis AG
18.8. Pfizer Inc.
18.9. Takeda Pharmaceutical Company Limited
18.10. Viatris Inc.

19. Appendix
19.1. Discussion Guide
19.2. License & Pricing

List of Figures
FIGURE 1. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET DYNAMICS
FIGURE 8. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2030
FIGURE 12. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS3/4A PROTEASE, 2018-2030 (USD MILLION)
FIGURE 13. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A PROTEIN, 2018-2030 (USD MILLION)
FIGURE 14. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B RNA-DEPENDENT RNA POLYMERASE, 2018-2030 (USD MILLION)
FIGURE 15. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 16. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2030
FIGURE 18. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS, 2018-2030 (USD MILLION)
FIGURE 19. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV INFECTION/ AIDS, 2018-2030 (USD MILLION)
FIGURE 20. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INFLUENZA, 2018-2030 (USD MILLION)
FIGURE 21. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
FIGURE 22. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2022 VS 2030 (%)
FIGURE 23. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET COMPETITIVE STRATEGIC WINDOW, BY ROUTE, 2030
FIGURE 25. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
FIGURE 26. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
FIGURE 27. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
FIGURE 28. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
FIGURE 29. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
FIGURE 30. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 31. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET COMPETITIVE STRATEGIC WINDOW, BY DISTRIBUTION CHANNEL, 2030
FIGURE 32. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
FIGURE 33. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE DRUG STORE, 2018-2030 (USD MILLION)
FIGURE 34. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
FIGURE 35. CALIFORNIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 36. FLORIDA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 37. ILLINOIS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 38. NEW YORK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 39. OHIO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 40. PENNSYLVANIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 41. TEXAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 42. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 43. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 44. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022List of Tables
TABLE 1. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 5. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS3/4A PROTEASE, 2018-2030 (USD MILLION)
TABLE 7. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS3/4A PROTEASE, BY STATE, 2018-2030 (USD MILLION)
TABLE 8. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A PROTEIN, 2018-2030 (USD MILLION)
TABLE 9. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A PROTEIN, BY STATE, 2018-2030 (USD MILLION)
TABLE 10. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B RNA-DEPENDENT RNA POLYMERASE, 2018-2030 (USD MILLION)
TABLE 11. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B RNA-DEPENDENT RNA POLYMERASE, BY STATE, 2018-2030 (USD MILLION)
TABLE 12. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 13. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS, 2018-2030 (USD MILLION)
TABLE 14. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS, BY STATE, 2018-2030 (USD MILLION)
TABLE 15. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV INFECTION/ AIDS, 2018-2030 (USD MILLION)
TABLE 16. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV INFECTION/ AIDS, BY STATE, 2018-2030 (USD MILLION)
TABLE 17. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INFLUENZA, 2018-2030 (USD MILLION)
TABLE 18. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INFLUENZA, BY STATE, 2018-2030 (USD MILLION)
TABLE 19. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2030 (USD MILLION)
TABLE 20. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROPHYLAXIS, BY STATE, 2018-2030 (USD MILLION)
TABLE 21. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INTRAVENOUS, BY STATE, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ORAL, BY STATE, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBCUTANEOUS, BY STATE, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TOPICAL, BY STATE, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY STATE, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE DRUG STORE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE DRUG STORE, BY STATE, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. CALIFORNIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 38. CALIFORNIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 39. CALIFORNIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. CALIFORNIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 41. CALIFORNIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. FLORIDA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 43. FLORIDA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. FLORIDA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. FLORIDA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 46. FLORIDA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. ILLINOIS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 48. ILLINOIS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. ILLINOIS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. ILLINOIS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 51. ILLINOIS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. NEW YORK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 53. NEW YORK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. NEW YORK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. NEW YORK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 56. NEW YORK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. OHIO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 58. OHIO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. OHIO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. OHIO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 61. OHIO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. PENNSYLVANIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 63. PENNSYLVANIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. PENNSYLVANIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. PENNSYLVANIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 66. PENNSYLVANIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. TEXAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 68. TEXAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. TEXAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. TEXAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 71. TEXAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 73. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 74. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 75. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET RANKING, BY KEY PLAYER, 2022
TABLE 76. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2022
TABLE 77. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 78. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET MERGER & ACQUISITION
TABLE 79. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 80. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 81. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET INVESTMENT & FUNDING
TABLE 82. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 83. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET: LICENSE & PRICING